Table 3.
Adjusted risk of all-cause and psychiatric hospitalizations and hospital length of stay (LOS) during the 24-month follow-up period.*
| Lurasidone† | Aripiprazole | Olanzapine | Quetiapine | Risperidone | Ziprasidone | No/minimal treatment | Other treatment | AAP monotherapy | |
|---|---|---|---|---|---|---|---|---|---|
| Treatment months | 10,863 | 17,554 | 7028 | 32,813 | 11,355 | 7600 | 59,370 | 87,402 | 28,813 |
| Hospitalizations rate, per 100-patient mo | |||||||||
| All causes | 2.36 | 2.70 | 3.67‡ | 2.96§ | 2.30 | 3.85§ | 2.19 | 3.52‡ | 3.03§ |
| Psychiatric | 1.97 | 2.24 | 3.11§ | 2.49§ | 1.96 | 2.99§ | 1.84 | 3.13‡ | 2.55§ |
| Hospital LOS, per 100-patient mo | |||||||||
| All causes | 12.21 | 15.14 | 20.29§ | 16.02§ | 13.86 | 18.70 | 14.19 | 20.25‡ | 17.72‡ |
| Psychiatric | 10.51 | 11.32 | 16.35 | 12.48 | 10.86 | 14.11 | 11.48 | 17.54‡ | 13.96§ |
AAP = atypical antipsychotics.
Boldface type indicates significance of outcomes in comparison to lurasidone at P < 0.05. Adjusted rates control for patient demographic characteristics, clinical characteristics, and health care utilization as well as time-varying indicators of key clinical characteristics, health care utilization, and time trends. Adjusted hospitalization rates will not precisely match adjusted odds ratios. Adjusted rates are calculated at the patient-level from each patient's predicted log odds, then averaged across the sample. The nonlinear conversion from log odds to predicted rates leads to minor differences if adjusted odds ratios are then back-calculated from the predicted rates.
Reference category.
Indicates significance versus lurasidone at P < 0.01.
Indicates significance versus lurasidone at P < 0.05.